Literature DB >> 2536003

A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues.

N R Ling1, D Hardie, J Lowe, G D Johnson, M Khan, I C MacLennan.   

Abstract

Cells of 7 EBV-B-LCL, 10 Burkitt lines and 13 EBV-B-LCL/Burkitt line hybrids have been phenotyped for antigens of the major B cell clusters and for some other antigens. High levels of CD23 and CD39 and low levels of CD38 (T10) were characteristic of EBV-B-LCL; the converse was true for Burkitt lines. In hybrids the EBV-LCL phenotype was dominant. The phenotype of Burkitt-line cells correlated strongly with that of germinal centre B cells in tonsil sections, but differed markedly from that of marginal zone B cells or follicular mantle cells. The results are discussed in relation to the origin of Burkitt tumours of "sporadic" and "endemic" type, in particular to histopathological evidence that Burkitt lymphomas develop in germinal centres. Recent studies on the location of the breakpoints of Burkitt chromosomal translocations are also considered to be compatible with this concept, even though different regions of the immunoglobulin heavy chain locus are involved in the two types of BL.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536003     DOI: 10.1002/ijc.2910430122

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL)

Authors:  N R Ling; F K Stevenson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

2.  c-Rel plays a key role in deficient activation of B cells from a non-X-linked hyper-IgM patient.

Authors:  Kristina T Lu; Frank L Sinquett; Rebecca L Dryer; Charles Song; Lori R Covey
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

3.  Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

Authors:  R B Gayle; C R Maliszewski; S D Gimpel; M A Schoenborn; R G Caspary; C Richards; K Brasel; V Price; J H Drosopoulos; N Islam; T N Alyonycheva; M J Broekman; A J Marcus
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

4.  Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes.

Authors:  U Klein; G Klein; B Ehlin-Henriksson; K Rajewsky; R Küppers
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

5.  Host factors LR1 and Sp1 regulate the Fp promoter of Epstein-Barr virus.

Authors:  S Bulfone-Paus; L A Dempsey; N Maizels
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.

Authors:  R A Baiocchi; J S Ward; L Carrodeguas; C F Eisenbeis; R Peng; S Roychowdhury; S Vourganti; T Sekula; M O'Brien; M Moeschberger; M A Caligiuri
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

7.  Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model.

Authors:  John M Buergler; Charles R Maliszewski; M Johan Broekman; Grzegorz L Kaluza; Daryl G Schulz; Aaron J Marcus; Albert E Raizner; Neal S Kleiman; Nadir M Ali
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

8.  Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.

Authors:  N Ling; T Hansel; P Richardson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

9.  A novel B lymphocyte-associated adaptor protein, Bam32, regulates antigen receptor signaling downstream of phosphatidylinositol 3-kinase.

Authors:  A J Marshall; H Niiro; C G Lerner; T J Yun; S Thomas; C M Disteche; E A Clark
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

Review 10.  STAT1 and pathogens, not a friendly relationship.

Authors:  Imen Najjar; Remi Fagard
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.